(Q37075859)

18 August 2017

1 reference

title

Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim (English)

1 reference

18 August 2017

0 references

Thomas Laughren

1

1 reference

18 August 2017

Robert Levin

series ordinal

2

1 reference

18 August 2017

language of work or name

English

0 references

publication date

3 August 2005

1 reference

18 August 2017

Schizophrenia Bulletin

1 reference

18 August 2017

32

1 reference

18 August 2017

2

1 reference

18 August 2017

220-222

1 reference

The NIMH-MATRICS consensus statement on negative symptoms

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632229

Comorbid mood disorders and medical illness: a Food and Drug Administration perspective

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632229

Negative symptoms in schizophrenia. Definition and reliability

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632229

A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632229

A regulatory perspective on psychiatric syndromes in Alzheimer disease.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632229

4 September 2018

Identifiers

DOI

10.1093/SCHBUL/SBI039

1 reference

18 August 2017

1 reference

18 August 2017

PubMed publication ID

16079389

1 reference